1Keys, A. Coronary heart disease in seven countries. Circulation 1970; 41: 11–211.
2Gotto, AM Jr. High density lipoprotein cholesterol and triglycerides as therapeutic targets for preventing and treating coronary artery disease. American Heart Journal 2002; 144: S33–S42.
3Yudkin, J, Kang, SS, Bruckdorfer, KR. Effects of high dietary sugar. British Medical Journal 1980; 281: 1396.
4Jeppesen, J, Hein, HO, Saudicani, P, Gyntelberg, F. High triglycerides/low high-density lipoprotein cholesterol, ischemic electrocardiogram changes, and risk of ischemic heart disease. American Heart Journal 2003; 145: 103–8.
5Zieden, B, Kaminskas, A, Kristenson, M, Olsson, AG, Kucinskiene, Z. Long chain polyunsaturated fatty acids may account for higher low-density lipoprotein oxidation susceptibility in Lithuanian compared to Swedish men. Scandinavian Journal of Clinical and Laboratory Investigation 2002; 62: 307–14.
6Nisbett, EF, Rossiter, AH, Miller, AR, Thacker, D. Fat is short dough biscuits. Flour Milling and Baking Research Association. 1986; (2): 63–77.
7Davis, MM, Jones, DW. The role of lifestyle management in the overall treatment plan for prevention of management of hypertension. Seminars in Nephrology 2002; 22: 35–43.
8Franklin, SS, Khan, SA, Wong, ND, Larson, MG, Levy, D. Is pulse pressure useful in predicting risk factors for coronary heart disease? The Framingham Heart Study. Circulation 1999; 100: 354–60.
9Van den Hoogen, PC, Feskens, EJ, Nagelkerke, NJ, Menotti, A, Nissinen, A, Kromhout, D. The relation between blood pressure and mortality due to coronary heart disease among men in different parts of the world. Seven Countries Study Research Group. New England Journal of Medicine 2000; 342: 1–8.
10He, J, Ogden, LG, Vupputuri, S, Bazzano, L, Loria, C, Whelton, PK. Dietary sodium intake and myocardial infarction. Journal of the American Medical Association 1999; 282: 2027–34.
11Krauss, RM, Deckelbaum, RJ, Ernst, N, Fisher, E, Howard, BV, Knopp, RH, et al. Dietary guidelines for healthy American adults: a statement for health professionals from the nutrition committee, American Heart Association. Circulation 1996; 94: 1795–800.
12Pietinen, P, Rimm, EB, Korhonen, P, Hartman, AM, Willett, WC, Albanes, D, et al. Intake of dietary fibre and risk of coronary heart disease in a cohort of Finnish men. The alpha-Tocopherol Beta-Carotene Prevention Study. Circulation 1996; 94: 2720–7.
13Rimm, EB, Ascherio, A, Giovannucci, E, Spiegelman, D, Stampfer, MJ, Willett, WC. Vegetable, fruit and cereal fibre intake and risk of coronary heart disease among men. Journal of the American Medical Association 1996; 275: 447–51.
14McCully, KS. Vascular pathology of homocysteinemia: implications for the pathogenesis of arteriosclerosis. American Journal of Pathology 1969; 56: 111–28.
15Klerk, M, Verhoef, P, Verbruggen, B, Schouten, EG, Blom, HJ, Bos, GM, et al. Effect of homocysteine reduction by B vitamin supplementation on marker of clotting activation. Thrombosis and Haemostasis 2002; 88: 230–5.
16Billion, S, Tribout, B, Cadet, E, Queinnec, C, Rochette, J, Wheatley, P, et al. Hyperhomocysteinemia, folate and vitamin B12 in unsupplemented haemodialysis patients: effect of oral therapy with folic acid and vitamin B12. Nephrology, Dialysis, Transplantation 2002; 17: 455–61.
17Genest, F Jr. Homocysteine: to screen and treat or wait and see? Canadian Medical Association Journal 2000; 163: 37–8.
18Hoefler, G, Harnoncourt, F, Pashcke, E, Mirtl, W, Pfeiffer, KH, Kostner, GM. Lipoprotein(a) Lp(a). A risk factor for myocardial infarction. Arteriosclerosis 1988; 8: 394–401.
19Sandkamp, M, Funke, H, Schulte, EK, Assman, G. Lipoprotein(a) is an independent risk factor for myocardial infarction at a young age. Clinical Chemistry 1990; 36: 20–3.
20Rosengren, A, Wilhelmsen, L, Eriksson, E, Risberg, B, Wedel, H. Lipoprotein (a) and coronary heart disease: a prospective case control study in a general population sample of middleaged men. British Medical Journal 1990; 301: 1248–51.
21Batiste, MC, Schaefer, EJ. Diagnosis and management of lipoprotein abnormalities. Nutrition in Clinical Care 2002; 5: 115–23.
22Pieper, JA. Understanding niacin formulations. American Journal of Managed Care 2002; 8: S308–14.
23Pan, J, Van, JT, Chan, RL, Lin, M, Charles, MA. Extended-release niacin treatment of the atherogenic lipid profile and lipoprotein (a) in diabetes. Metabolism 2002; 52: 1120–7.